ReviewLipids in health and disease2025
Breaking the metabolic-inflammatory vicious cycle in polycystic ovary syndrome: a comparative review of ketogenic and high-fat diets.
Review in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Leptin, adiponectin levels and their ratios in women with polyendocrine metabolic ovarian syndrome: a systematic review and meta-analysis.Frontiers in medicine · 2026Pooled it
- Low-Carbohydrate (Ketogenic) Diet in Children with Obesity: Part 2-Hormonal Effects of the Ketogenic Diet.Children (Basel, Switzerland) · 2026Article
- Decoding the gut-adipose-ovary axis in polycystic ovary syndrome: from metabolic dysregulation to oncological risk modulation.Frontiers in microbiology · 2026Review
- The role of intestinal microbial metabolites in polycystic ovary syndrome: mechanistic insights and intervention prospects.Frontiers in endocrinology · 2026Review
- Effects of polycystic ovary syndrome on liver, heart, muscle, and pancreatic-related diseases.Frontiers in endocrinology · 2026Review
- Amniotic-fluid metabolomics identifies phospholipid remodeling as a metabolic signature of intrauterine exposure in pregnancies with polycystic ovary syndrome.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovary syndrome (PCOS) is a multifactorial metabolic-endocrine disorder in women of reproductive age in which lipid metabolism disorders and chronic low-grade inflammation reinforce and amplify each other. Recently, the ketogenic diet (KD), which is a high-fat, very-low-carbohydrate dietary intervention, has drawn attention because of its metabolic regulation and anti-inflammatory properties. This review integrates current evidence to elucidate how aberrant fatty acid turnover, adipose tissue dysfunction, and adipokine imbalance trigger convergent proinflammatory pathways, thus forming an "inflammatory hub" that links insulin resistance, hyperandrogenemia, impaired folliculogenesis, and heightened cardiovascular risk in PCOS. The mechanisms by which strict carbohydrate restriction promotes fatty acid β-oxidation and hepatic ketogenesis are delineated, thereby reprogramming cellular metabolism. The principal ketone body, β-hydroxybutyrate, directly suppresses the nucleotide-binding oligomerization domain-like receptor family pyrin domain containing 3 inflammasome, remodels the gut microbiota, and attenuates nuclear factor kappa-light-chain-enhancer of activated B cells signaling, thus yielding multitarget anti-inflammatory effects. Unlike isocaloric high-fat diets, which lead to obesity, inflammation, and insulin resistance, the KD lowers triacylglycerols and the proportion of small, dense low-density lipoprotein particles; enhances whole-body insulin sensitivity; and mitigates systemic inflammation. Collectively, the KD offers a multidimensional intervention that couples metabolic correction with immune modulation and holds promise for improving PCOS trajectories and long-term complications. Nevertheless, its long-term safety profile, lipid subclass optimization, and biomarker-driven personalization require further investigation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.